Phlogenzym 100 enteric-coated tablets

In complex therapy and prevention of the following diseases:
Surgery: postoperative recovery and rehabilitation of patients (improvement of reparative processes and regeneration), postoperative purulent-inflammatory complications, prevention of adhesive disease and keloid scar formation, reduction of the risk of thromboembolic complications during prolonged immobilization.
Traumatology: bone fractures, tendon and ligament injuries, bruises and hematomas of soft tissues, sports injuries, burns, improvement of prosthesis integration, osteosynthesis.
Angiology: thrombophlebitis of superficial veins, post-thrombotic disease, obliterating atherosclerosis of the lower limb arteries and other chronic angiopathies, microcirculation disorders, lymphatic edema (lymphedema).
Urology: acute and chronic inflammation of the urogenital tract (cystitis, urethritis, prostatitis).
Gynecology: vascular complications of the climacteric period, reduction of the frequency and severity of complications of hormone replacement therapy.
Cardiology: ischemic heart disease, reduction of the risk of vascular catastrophes and recurrent heart attacks.
Gastroenterology: hepatitis.
Rheumatology: rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, rheumatic lesions of soft tissues.
Neurology: ischemic stroke, multiple sclerosis.
Pulmonology: chronic obstructive pulmonary disease.
Dentistry: prevention of complications in the postoperative period after tooth extraction, purulent-inflammatory diseases of the maxillofacial area, rehabilitation and recovery after surgical interventions in the maxillofacial area, improvement of implant integration, osteosynthesis.

The tablets are taken orally, at least 30 minutes before meals, without chewing, and with water (200 ml). After surgery, it is recommended to start taking the medication from the 2nd or 3rd day.

Treatment
The medication is taken after injuries and surgeries or in cases of acute inflammation to break down and remove damaged tissues, absorb hematomas, improve tissue trophism and reparative processes, reduce inflammation and swelling, and lower the risk of complications - thrombosis, development of adhesive disease, formation of keloid scars, and wound suppuration, at a dosage of 3 tablets 3 times a day for 2 weeks. If necessary, to enhance recovery and healing, the course of the medication may be extended to 4 weeks or more at a dosage of 2 tablets 3 times a day.

Prevention of Complications
To prevent long-term consequences after surgery - thromboembolic complications, development of abdominal adhesive disease, trophic disorders during prolonged bed rest and immobilization of the patient, it is recommended to take the medication for an extended course at a dosage of 2 tablets 3 times a day for 4 weeks or more, or for the entire duration of immobilization.

Use with Antibiotics
When antibiotics are prescribed, the medication is used to enhance the effectiveness of antibiotic therapy and reduce the undesirable effects of antibiotics. It is recommended to take the medication throughout the entire course of antibiotic therapy at a dosage of 2 tablets 3 times a day.

Use with Hormones
When long courses of hormones are prescribed, the medication is recommended to reduce the risk of complications (thrombosis) at a dosage of 2 tablets 3 times a day for the entire duration of hormone therapy. In the case of hormone replacement therapy (HRT), to reduce the risk of thrombosis in the veins of the lower extremities, it is recommended to take 2 tablets 3 times a day in repeated courses of 2 weeks with breaks of 3 weeks, 3-4 times a year.

Prevention
To prevent thrombosis of the veins in the lower extremities and reduce the risk of vascular catastrophes (myocardial infarction), it is recommended to take the medication at a dosage of 2 tablets 3 times a day for a course of at least 3-4 weeks, repeating the courses 3-4 times a year.

Changes to the course and dosages of the medication are recommended after consulting a doctor.

If there is no improvement after treatment, or if symptoms worsen, or new symptoms appear, it is necessary to consult a doctor. Use the medication only according to the method of application and in the dosages specified in the instructions.

1 enteric-coated tablet contains:
Core:
Active ingredients: bromelain 450 FIP units (90.0 mg), trypsin 1440 FIP units (48.0 mg), rutin trihydrate 100.0 mg.
Excipients: lactose monohydrate 148 mg, pregelatinized starch 24.0 mg, magnesium stearate 12.7 mg, stearic acid 11.3 mg, colloidal silicon dioxide 6.36 mg, talc 2.46 mg.

Round, biconvex tablets coated with a film, yellowish-green in color, with a characteristic odor.

Individual intolerance to the components of the drug. Congenital or acquired blood coagulation disorders. Pediatric age.

WITH CAUTION (after consulting a doctor)
Hemodialysis.

In the case of infectious processes, FLOHENZYM does not replace antibiotics.
In the event of an exacerbation of the underlying disease while taking the medication, a temporary reduction in the dosage or temporary discontinuation of the medication is recommended after consulting a doctor.
The medication is not a doping agent and does not negatively affect driving or performing tasks that require high speed of mental and physical reactions.
Patients with diabetes should note that each tablet of the medication contains 0.015 bread units.

The medication is well tolerated by patients. In some cases, increased stool frequency, changes in stool consistency and odor may occur, which quickly resolve with a temporary reduction in the medication dosage. Rarely, an allergic reaction (skin rash, itching) may occur, which disappears after dose reduction or discontinuation of the medication. If the conditions of use are violated, nausea, bloating, abdominal pain, headache, dizziness, rash, general weakness, and a feeling of intestinal fullness may arise. These conditions disappear after reducing the dosage or temporarily discontinuing the medication.
If you experience side effects listed in the instructions, or if they worsen, or if you notice any other side effects not mentioned in the instructions, please inform your doctor.

Cases of overdose of the drug are unknown.

No cases of incompatibility with other medications have been reported. The use of the drug in conjunction with antibiotics increases the effectiveness of antibiotic therapy. When used with hormones, the drug reduces the risk of thrombosis.
If you are using the above-mentioned or other medications (including over-the-counter) before using the drug Phlogenzyme, consult your doctor.

FLOGENZYM is a next-generation medication consisting of a combination of highly active proteolytic enzymes (ferments) of plant and animal origin - bromelain and trypsin, combined with rutin. In combination, the enzymes exert pleiotropic (multiple) effects, possessing various pharmacological actions on pathophysiological and biochemical processes. The enzymes of the preparation implement their therapeutic effects through anti-inflammatory, immunomodulatory, anti-aggregant, fibrinolytic, thrombolytic, anti-edematous, and secondarily analgesic actions. The enteric-coated tablets of the preparation transiently pass through the upper gastrointestinal tract without damaging the stomach, being absorbed in the small intestine through the resorption of intact molecules (endocytosis, pinocytosis). The proteases of the preparation, binding to blood transport proteins (alpha-2-macroglobulin and alpha-1-antitrypsin), form a reversible protease-antiprotease complex, in which the antigenic determinants of the preparation's exogenous proteases are masked, preventing allergic reactions. As a result of the formation of the complex with the enzymes, the antiprotease (alpha-2-macroglobulin) transitions to an active form, which performs the function of an extracellular regulator of pro-inflammatory cytokines and growth factors, facilitating their transport, clearance, and elimination.

The formation of the active protease-antiprotease complex allows for the safe transport of proteolytic enzymes through the vascular system to the site of inflammation and injury, regardless of the location in the body. The complex retains and slows the elimination of the preparation's proteolytic enzymes from the body, increasing their circulation time in the vascular system and, consequently, the therapeutic effect. Upon reaching the site of inflammation and wounds, the proteolytic enzymes cleave (hydrolyze) damaged proteins and tissues and eliminate (remove) cellular debris (detritus), promoting accelerated cleansing and healing of the wound.

The preparation positively influences the course of the inflammatory process, modulating the body's protective responses, which contributes to the physiological progression of inflammation at various stages. The proteolytic enzymes of the preparation accelerate the breakdown of inflammatory mediators, cleave immune complexes and membrane deposits, enhance the activity of phagocytes and natural killer cells, and stimulate interferonogenesis. The proteases of the preparation reduce the levels of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, INF-γ, TNF-α) and promote the increased production of anti-inflammatory cytokines (IL-4, IL-10, etc.), regulating the levels of immunoglobulins and antibodies in the blood. The enzymes of the preparation limit the pathological manifestations of autoimmune and immune complex processes, restoring the immunological reactivity of the body.

The proteases of the preparation reduce the level of transforming growth factor-beta, the increase of which leads to excessive scarring. The proteolytic enzymes exert a regulatory effect on the synchronization of the processes of basal membrane (laminin) formation, modulation of the wound process, and expression of angiogenesis factors (vascular endothelial growth factor, fibroblast growth factor, and several other factors). Thus, the enzymes of the preparation contribute to the improvement of reparative processes, prevention of hypertrophic and keloid scar formation, and the development of adhesive disease after surgical interventions in the abdominal cavity.

The enzymes of the preparation cleave and remove damaged tissues, accelerate the resorption of hematomas and edema by normalizing the permeability of vessel walls, reducing the infiltration of the interstitium by plasma proteins, increasing the elimination of protein detritus and fibrin deposits, and improving microcirculation and trophic processes in the area of damage. The optimization of the inflammatory process by proteolytic enzymes through the reduction of oncotic pressure and tissue edema, lowering pressure on nerve endings, eliminating ischemia, and normalizing microcirculation, along with direct proteolysis of inflammatory mediators, allows the proteases to exert a secondary analgesic effect. Simultaneously, the proteolytic enzymes stimulate healing and reparative processes, reduce the risk of thromboembolic complications during prolonged immobilization, and prevent the development of trophic disorders and purulent complications. The enzymes of the preparation positively influence the improvement of microcirculation, increase the delivery of oxygen and nutrients to the wound, reduce inflammation at the site of damage, support the physiological process of regeneration, and accelerate the restoration of organ and tissue function.

The preparation improves the rheological properties of blood (viscosity and flow) due to its positive effect on the functional state of blood cells and the vascular wall, the plasticity (deformability) of erythrocytes, stabilization of endothelial permeability, increased fibrinolytic activity of serum, reduced density of adhesive molecules, and decreased aggregation (clumping) of platelets. The proteolytic enzymes reduce the number of activated forms of platelets (spheroechinocytes) and micro and macroaggregates, thereby decreasing the risk of thrombosis in blood vessels while simultaneously participating in the lysis of formed clots. The proteolytic enzymes lower the levels of atherogenic lipids, promoting an increase in high-density lipoproteins, reducing the risk of atherosclerosis and vascular disorders.

The preparation improves blood supply to the bronchi and lung tissue in chronic respiratory diseases, including those caused by smoking, enhances the viscosity properties of bronchial secretions, the function of ciliated epithelium, restores the drainage function of the bronchi, and liquefies sputum, facilitating breathing and reducing cough.

The proteolytic enzymes of the preparation enhance the effectiveness of antibiotics while simultaneously reducing the undesirable effects of antibiotic therapy (dysbiosis, irritable bowel syndrome). The proteases improve the breakdown of substrates, optimize the balance of microbiota, and contribute to the restoration of intestinal endoecology.

Phlogenzyme is a medicinal product consisting of highly active proteolytic enzymes of plant and animal origin combined with rutin.
Phlogenzyme is used for the comprehensive treatment and prevention of complications after surgeries and injuries, as well as in cases of acute inflammation.
Phlogenzyme is applied in:
• surgery, urology, and gynecology (including for recovery after surgeries and prevention of adhesions),
• traumatology (including after fractures, after arthroplasty and osteosynthesis),
• dentistry (including to prevent complications in the postoperative period after tooth extraction, to improve implant integration, in osteosynthesis, in the treatment of purulent-inflammatory diseases of the maxillofacial area),
• and other fields of medicine.
Phlogenzyme has multiple effects:
• anti-edematous,
• anti-inflammatory,
• secondarily analgesic,
• immunomodulatory,
• fibrinolytic,
• thrombolytic,
• anti-aggregant,
• enhances the effectiveness of antibiotics.
The enzymes in the product positively influence the improvement of microcirculation, increase the delivery of oxygen and nutrients to the wound, reduce inflammation at the site of damage, support the physiological process of regeneration, and accelerate the recovery of organ and tissue function. The tablets are taken orally, at least 30 minutes before meals, without chewing, with water (200 ml). After surgery, it is recommended to start taking the product from the 2nd-3rd day. It is advisable to consult a doctor before use.